A share price of Ovid Therapeutics Inc [OVID] is currently trading at $1.13, up 11.88%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OVID shares have gain 23.50% over the last week, with a monthly amount glided 10.78%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ovid Therapeutics Inc [NASDAQ: OVID] stock has seen the most recent analyst activity on June 18, 2024, when Oppenheimer downgraded its rating to a Perform. Previously, B. Riley Securities started tracking the stock with Buy rating on April 30, 2024, and set its price target to $9. On April 29, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $9 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $8 on April 05, 2024. BTIG Research initiated its recommendation with a Buy and recommended $11 as its price target on December 21, 2023. Oppenheimer started tracking with a Outperform rating for this stock on October 13, 2023, and assigned it a price target of $8. In a note dated April 20, 2021, Cantor Fitzgerald downgraded an Neutral rating on this stock but restated the target price of $4.
Ovid Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.68 and $4.14. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $1.13 at the most recent close of the market. An investor can expect a potential return of 548.67% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Trailing Twelve Months sales for Ovid Therapeutics Inc [NASDAQ:OVID] were 0.57M which represents 125.33% growth. Gross Profit Margin for this corporation currently stands at 191.61% with Operating Profit Margin at -120.08%, Pretax Profit Margin comes in at -52.42%, and Net Profit Margin reading is -52.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.33 and Total Capital is -0.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0401 points at the first support level, and at 0.9501 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1800, and for the 2nd resistance point, it is at 1.2299.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ovid Therapeutics Inc [NASDAQ:OVID] is 5.73. As well, the Quick Ratio is 5.73, while the Cash Ratio is 2.1. Considering the valuation of this stock, the price to sales ratio is 140.69, the price to book ratio is 0.90.
Transactions by insiders
Recent insider trading involved LEVIN JEREMY M, CEO, that happened on Mar 18 ’24 when 18248.0 shares were purchased.
